AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca, in collaboration with Parexel, is conducting a Phase IIIb study titled ‘ACADIA’ to evaluate the efficacy and safety of two inhalers, PT027 and PT007, for adolescents with asthma. The study aims to compare the impact of a budesonide/albuterol metered-dose inhaler (BDA MDI) with an albuterol sulfate metered-dose inhaler (AS MDI) on reducing severe asthma exacerbations over a year.
The interventions being tested are BDA MDI and AS MDI, both combination products administered as needed. BDA MDI is an experimental treatment, while AS MDI serves as the active comparator.
The study follows a randomized, double-blind, parallel-group design, focusing on treatment as its primary purpose. Participants and investigators are blinded to the treatment allocation.
The study began on May 20, 2024, with a primary completion date projected for 2025. The latest update was submitted on July 10, 2025. These dates are crucial for tracking the study’s progress and potential market entry timelines.
This study’s progress could influence AstraZeneca’s stock performance by potentially enhancing its respiratory treatment portfolio. Positive outcomes might boost investor confidence, especially in a competitive industry where innovation is key.
The study is currently recruiting, with further details available on the ClinicalTrials portal.